Targeting the interleukin pathway in the treatment of asthma (Q38588854)

4 September 2017

title

Targeting the interleukin pathway in the treatment of asthma (English)

1 reference

4 September 2017

0 references

Kian Fan Chung

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 September 2015

1 reference

4 September 2017

1 reference

4 September 2017

volume

386

1 reference

4 September 2017

issue

9998

1 reference

4 September 2017

page(s)

1086-1096

1 reference

The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

New targets for drug development in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Allergens and the airway epithelium response: gateway to allergic sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Innate and adaptive immune responses in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

The cell biology of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

1 reference

7 January 2021

Cytokine targets in airway inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Cluster analysis and clinical asthma phenotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

How variability in clinical phenotypes should guide research into disease mechanisms in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Asthma phenotypes: the evolution from clinical to molecular approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Lebrikizumab Treatment in Adults with Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Epithelial cytokines and pulmonary allergic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

TH2, allergy and group 2 innate lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Targeting interleukin-4 in asthma: lost in translation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Interleukin-13: central mediator of allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Dupilumab in persistent asthma with elevated eosinophil levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Mepolizumab and exacerbations of refractory eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Reslizumab for Poorly Controlled, Eosinophilic Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

MicroRNA-375 regulation of thymic stromal lymphopoietin by diesel exhaust particles and ambient particulate matter in human bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Increased IL-33 expression by epithelial cells in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Thymic stromal lymphopoietin promotes asthmatic airway remodelling in human lung fibroblast cells through STAT3 signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Effects of an anti-TSLP antibody on allergen-induced asthmatic responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

T helper 17 cells in airway diseases: from laboratory bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Mode of dendritic cell activation: the decisive hand in Th2/Th17 cell differentiation. Implications in asthma severity?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

Evidence of a role of tumor necrosis factor alpha in refractory asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900157-9

7 January 2021

10.1016/S0140-6736(15)00157-9

Identifiers

DOI

1 reference

release_chicy3zunzerngqteoa4kqpcs4

4 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/chicy3zunzerngqteoa4kqpcs4

24 November 2022

mapped directly with Wikidata item

1 reference